A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Symphogen A/S
Xencor, Inc.
Incyte Corporation
AbbVie
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Centre Hospitalier Universitaire de Nice
Masonic Cancer Center, University of Minnesota
Stanford University
Valerio Therapeutics
Valerio Therapeutics
University of Chicago